NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News & Analysis

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group Inc (NASDAQ:CBMG) issued its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.10. Cellular Biomedicine Group had a negative net margin of 17,921.62% and a negative return on equity of 44.32%. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Cellular Biomedicine Group.

3 equities research analysts have issued 1-year target prices for Cellular Biomedicine Group's stock. Their predictions range from $26.00 to $38.00. On average, they expect Cellular Biomedicine Group's stock price to reach $30.3333 in the next year. This suggests a possible upside of 125.0% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

News headlines about CBMG stock have trended negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of -2.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cellular Biomedicine Group.

Cellular Biomedicine Group saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 510,200 shares, a decrease of 5.1% from the June 30th total of 537,400 shares. Based on an average trading volume of 34,600 shares, the short-interest ratio is presently 14.7 days. Approximately 4.6% of the company's stock are sold short. View Cellular Biomedicine Group's Current Options Chain.

Some companies that are related to Cellular Biomedicine Group include NanoString Technologies (NSTG), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Adverum Biotechnologies (ADVM), Rubius Therapeutics (RUBY), Cortexyme (CRTX), Voyager Therapeutics (VYGR), Atara Biotherapeutics (ATRA), Krystal Biotech (KRYS), MeiraGTx (MGTX), Vericel (VCEL), Osiris Therapeutics (OSIR), GENFIT S A/ADR (GNFT), DBV TECHNOLOGIE/S (DBVT) and Cellectis (CLLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Adaptimmune Therapeutics (ADAP), Anthera Pharmaceuticals (ANTH), Editas Medicine (EDIT), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX) and Viewray (VRAY).

Cellular Biomedicine Group's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.89%), Platinum Investment Management Ltd. (3.50%), Nikko Asset Management Americas Inc. (2.77%), Sumitomo Mitsui Trust Holdings Inc. (2.75%), ARK Investment Management LLC (1.63%) and Vanguard Group Inc. (1.10%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BNP Paribas Arbitrage SA and Wells Fargo & Company MN. View Insider Buying and Selling for Cellular Biomedicine Group.

CBMG stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., AWM Investment Company Inc., ARK Investment Management LLC, Platinum Investment Management Ltd., Northern Trust Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $13.48.

Cellular Biomedicine Group has a market capitalization of $259.49 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.View Additional Information About Cellular Biomedicine Group.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com/.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]